Literature DB >> 16845513

Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries.

Iina Laitinen1, Päivi Marjamäki, Merja Haaparanta, Nina Savisto, V Jukka O Laine, Sanna L Soini, Ian Wilson, Pia Leppänen, Seppo Ylä-Herttuala, Anne Roivainen, Juhani Knuuti.   

Abstract

PURPOSE: [(18)F]FDG has been used as an inflammation marker and shown to accumulate in inflammatory atherosclerotic plaques. The aim of this study was to investigate the uptake and location of [(18)F]FDG in atherosclerotic plaque compartments.
METHODS: The biodistribution of intravenously administered [(18)F]FDG was analysed in atherosclerotic LDLR/ApoB48 mice (n=11) and control mice (n=9). Digital autoradiography was used to detect the ex vivo distribution in frozen aortic sections. In vitro binding of [(18)F]FDG in human atherosclerotic arteries was also examined.
RESULTS: The uptake of [(18)F]FDG was significantly higher in the aorta of atherosclerotic mice as compared with the control mice. Autoradiography of excised arteries showed higher [(18)F]FDG uptake in the plaques than in the healthy vessel wall (mean ratio +/-SD 2.7+/-1.1). The uptake of [(18)F]FDG in the necrotic, calcified sites of the advanced atherosclerotic lesions was 6.2+/-3.2 times higher than that in the healthy vessel wall. The in vitro studies of human arterial sections showed marked binding of [(18)F]FDG to the calcifications but not to other structures of the artery wall.
CONCLUSION: In agreement with previous studies, we observed [(18)F]FDG uptake in atherosclerotic plaques. However, prominent non-specific binding to calcified structures was found. This finding warrants further studies to clarify the significance of this non-specific binding in human plaques in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845513     DOI: 10.1007/s00259-006-0159-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  14 in total

1.  Association of vascular 18F-FDG uptake with vascular calcification.

Authors:  Mark P S Dunphy; Alvin Freiman; Steven M Larson; H William Strauss
Journal:  J Nucl Med       Date:  2005-08       Impact factor: 10.057

2.  Rationale for the role of osteoclast-like cells in arterial calcification.

Authors:  Terence M Doherty; Hiroyasu Uzui; Lorraine A Fitzpatrick; Pinky V Tripathi; Colin R Dunstan; Kamlesh Asotra; Tripathi B Rajavashisth
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

3.  Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice.

Authors:  Pia Leppänen; Suvi Koota; Ivana Kholová; Jonna Koponen; Christina Fieber; Ulf Eriksson; Kari Alitalo; Seppo Ylä-Herttuala
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

Review 4.  Pathophysiology of coronary artery disease.

Authors:  Peter Libby; Pierre Theroux
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

Review 5.  Mouse models of experimental atherosclerosis.

Authors:  J Jawień; P Nastałek; R Korbut
Journal:  J Physiol Pharmacol       Date:  2004-09       Impact factor: 3.011

6.  A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet.

Authors:  L Powell-Braxton; M Véniant; R D Latvala; K I Hirano; W B Won; J Ross; N Dybdal; C H Zlot; S G Young; N O Davidson
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

7.  Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

Authors:  M M Véniant; C H Zlot; R L Walzem; V Pierotti; R Driscoll; D Dichek; J Herz; S G Young
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

8.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.

Authors:  K Hamacher; H H Coenen; G Stöcklin
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

Review 9.  Molecular, endocrine, and genetic mechanisms of arterial calcification.

Authors:  Terence M Doherty; Lorraine A Fitzpatrick; Daisuke Inoue; Jian-Hua Qiao; Michael C Fishbein; Robert C Detrano; Prediman K Shah; Tripathi B Rajavashisth
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

10.  Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.

Authors:  J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg
Journal:  Circulation       Date:  2002-06-11       Impact factor: 29.690

View more
  16 in total

Review 1.  Gallium-labelled peptides for imaging of inflammation.

Authors:  Anne Roivainen; Sirpa Jalkanen; Cristina Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Direct relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro study.

Authors:  Cecilia Marini; Silvia Morbelli; Riccardo Armonino; Giovanni Spinella; Mattia Riondato; Michela Massollo; Francesca Sarocchi; Bianca Pane; Carla Augeri; Luca Abete; Giorgio Ghigliotti; Daniela Palmieri; Francesco Fiz; Giuseppe Cittadini; Ezio Fulcheri; Domenico Palombo; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-20       Impact factor: 9.236

3.  68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice.

Authors:  Seppo Ylä-Herttula; Juhani Knuuti; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

4.  Localization of deoxyglucose and annexin A5 in experimental atheroma correlates with macrophage infiltration but not lipid deposition in the lesion.

Authors:  Yan Zhao; Songji Zhao; Yuji Kuge; William H Strauss; Francis G Blankenberg; Nagara Tamaki
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

Review 5.  (18)F-FDG PET and vascular inflammation: time to refine the paradigm?

Authors:  Mehran M Sadeghi
Journal:  J Nucl Cardiol       Date:  2015-04       Impact factor: 5.952

Review 6.  PET imaging of aortic atherosclerosis: Is combined imaging of plaque anatomy and function an amaranthine quest or conceivable reality?

Authors:  Gary R Small; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2011-08       Impact factor: 5.952

7.  Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.

Authors:  Alexis Broisat; Sophie Hernot; Jakub Toczek; Jens De Vos; Laurent M Riou; Sandrine Martin; Mitra Ahmadi; Nicole Thielens; Ulrich Wernery; Vicky Caveliers; Serge Muyldermans; Tony Lahoutte; Daniel Fagret; Catherine Ghezzi; Nick Devoogdt
Journal:  Circ Res       Date:  2012-03-30       Impact factor: 17.367

8.  High resolution FDG-microPET of carotid atherosclerosis: plaque components underlying enhanced FDG uptake.

Authors:  Jin Liu; William S Kerwin; James H Caldwell; Marina S Ferguson; Daniel S Hippe; Adam M Alessio; Vanesa Martinez-Malo; Kristi Pimentel; Robert S Miyaoka; Ted R Kohler; Thomas S Hatsukami; Chun Yuan
Journal:  Int J Cardiovasc Imaging       Date:  2015-08-18       Impact factor: 2.357

Review 9.  Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries.

Authors:  Wengen Chen; Gonca G Bural; Drew A Torigian; Daniel J Rader; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-04       Impact factor: 9.236

10.  Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques.

Authors:  Iina Laitinen; Päivi Marjamäki; Kjell Någren; V Jukka O Laine; Ian Wilson; Pia Leppänen; Seppo Ylä-Herttuala; Anne Roivainen; Juhani Knuuti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.